Rize Oncology Inc.
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.50% | -34.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.14% | 6.35% | |||
| Operating Income | -7.14% | -6.35% | |||
| Income Before Tax | -6.49% | -8.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.49% | -8.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.49% | -8.14% | |||
| EBIT | -7.14% | -6.35% | |||
| EBITDA | -8.57% | -26.63% | |||
| EPS Basic | -3.45% | -7.41% | |||
| Normalized Basic EPS | -5.56% | -5.88% | |||
| EPS Diluted | -3.45% | -7.41% | |||
| Normalized Diluted EPS | -5.56% | -5.88% | |||
| Average Basic Shares Outstanding | 2.14% | 0.44% | |||
| Average Diluted Shares Outstanding | 2.14% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||